| Ytd | -38.95% | |
| 1y | -63.62% |
| Open | 0.72 | Prev Close | 0.72 | Low | 0.72 | High | 0.74 | Mkt Cap | 32.25M |
| Vol | 1.58K | Avg Vol | 153.31K | EPS | -0.78 | P/E | -0.92 | Forward P/E | -4.31 |
| Beta | 1.34 | Short Ratio | 1.28 | Inst. Own | 51.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 0.85 | 200-d Avg | 0.97 | 1yr Est | 9.20 |
TELA News
MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commer
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus E
MALVERN, Pa. , May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medi
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commerc
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage med
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a comme
TELA Bio (NASDAQ: TELA) reported fourth-quarter and full-year 2025 results that management character
TELA Bio, Inc. (NASDAQ: TELA) reported mixed results for the fourth quarter on Tuesday.
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus E
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage med
TELA Bio, Inc. (NASDAQ: TELA - Get Free Report) has received an average rating of "Hold" from the fi
MALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a comme
Quantum Genomics (OTCMKTS:QNNTF - Get Free Report) and TELA Bio (NASDAQ: TELA - Get Free Report) are
MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commer
TELA Bio, Inc. (NASDAQ: TELA - Get Free Report) has received an average rating of "Hold" from the fi
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commer
MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commer
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Monday